Zip Co Limited (ASX:ZIP) Announces 1H FY25 Results
Zip Co Limited (ASX:ZIP) reports a 117.1% increase in cash EBITDA for 1H FY25, driven by strong US growth and disciplined strategy execution.
Nine Entertainment Co. Holdings Ltd (ASX:NEC) Announces FY25 Interim Results
Nine Entertainment Co. Holdings Ltd (ASX:NEC) reports FY25 interim results, highlighting growth in streaming and digital revenue, cost efficiencies, and strong audience performance.
Fenix Resources (ASX:FEX) Launches Takeover Bid for CZR Resources (ASX:CZR)
Fenix Resources (ASX:FEX) initiates a takeover bid for all CZR Resources (ASX:CZR) shares, offering up to 0.98 Fenix Shares per CZR Share.
Noumi Limited (ASX:NOU) Releases Half-Year Financial Results
Noumi Limited (ASX:NOU) reports revenue slightly up and EBITDA growth in its half-year financial results, despite an increased net loss.
AUB Group Limited (ASX:AUB) Announces 1HFY25 Performance Overview
AUB Group (ASX:AUB) reports increased underlying NPAT and announces higher interim dividends for 1HFY25, highlighting revenue growth across divisions.
Dalrymple Bay Infrastructure Limited (ASX:DBI) Announces FY24 Financial Results
Dalrymple Bay Infrastructure (ASX:DBI) announces FY24 results with increased revenue, profit, and enhanced distribution guidance.
Waterco Limited (ASX:WAT) Reports HY25 Financial Results
Waterco Limited (ASX:WAT) reports a 14% sales increase in HY25 and declares a 7 cents interim dividend, with CEO anticipating stronger second-half performance.
GTN Limited (ASX:GTN) Announces Half-Year Results
GTN Limited (ASX:GTN) reports a 10.8% rise in net profit and declares an interim FY2025 dividend of $0.0247 per share.
OD6 Metals (ASX:OD6) Launches Maiden Drill Program at Gulf Creek
OD6 Metals (ASX:OD6) commences a 2,000m maiden drill program at the historically underexplored Gulf Creek Copper Project.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Rare Pediatric Disease Designation
Neuren Pharmaceuticals (ASX:NEU) receives FDA Rare Pediatric Disease Designation for NNZ-2591 in multiple syndromes, potentially qualifying for a priority review voucher.